Sertraline updated on 07-01-2025

Limb reduction defects (LRD)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7352
R21535		 Wemakor, 2015 Limb reduction 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.75 [0.04;12.60] C 0/14   784/17,853 784 14
ref
S6159
R16166		 Louik, 2007 Limb-reduction defects 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 3.90 [1.10;13.50] 3/49   190/6,004 193 49
ref
Total 2 studies 2.83 [0.79;10.15] 977 63
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wemakor, 2015Wemakor, 2015 0.75[0.04; 12.60]7841419%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Louik, 2007Louik, 2007 3.90[1.10; 13.50]1934981%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 9% 2.83[0.79; 10.15]977630.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 2.83[0.79; 10.15]977639%NAWemakor, 2015 Louik, 2007 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.83[0.79; 10.15]977639%NAWemakor, 2015 Louik, 2007 2 Tags Adjustment   - No  - No 0.75[0.04; 12.60]78414 -NAWemakor, 2015 1   - Yes  - Yes 3.90[1.11; 13.66]19349 -NALouik, 2007 1 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.75[0.04; 12.60]78414 -NAWemakor, 2015 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 3.90[1.11; 13.66]19349 -NALouik, 2007 1 All studiesAll studies 2.83[0.79; 10.15]977639%NAWemakor, 2015 Louik, 2007 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.83[0.79; 10.15]977639%NAWemakor, 2015 Louik, 2007 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Reefhuis (Any limb reduction)Reefhuis (Any limb reduction) 1.20[0.70; 2.00]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT3 metaPregmetaPreg 2.83[0.79; 10.15]9%63----Wemakor, 2015 Louik, 2007 20.510.01.0